CONMED Corporation (CNMD)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $1.47B
Last updated: Nov 17, 2026 at 4:10 PM ET
CONMED Corporation (CNMD) Statistics
CONMED (CNMD) has a market cap of $1.47B and an enterprise value of $2.24B. Its trailing P/E of 10.2x is below its 10-year median of 31.2x. Its share count is down 3.32% from a year earlier.
Total Valuation
Enterprise value is 52.21% above the market cap, as debt exceeds cash.
| Market Cap | $1.47B |
|---|---|
| Enterprise Value | $2.24B |
| Latest price (Nov 17, 2026) | $48.41 |
Key Dates
The next earnings report is expected on Jan 26, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Jan 26, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 28, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.1x and 1.4x. Its year-end P/E ranged from 8.8x to 51.9x from 2016 to 2025.
| P/E Ratio | 10.2x |
|---|---|
| Forward P/E | 10.4x |
| P/S Ratio | 1.1x |
| Forward P/S | 1.1x |
| P/B Ratio | 1.4x |
| P/FCF Ratio | 10.9x |
| P/OCF Ratio | 10.1x |
| PEG Ratio | 1.9 |
Enterprise Valuation
Counting debt and cash, the company is valued at 10.1x EBITDA and 16.7x free cash flow.
| EV / Earnings | 30.5x |
|---|---|
| EV / Sales | 1.6x |
| EV / EBITDA | 10.1x |
| EV / EBIT | 16.2x |
| EV / FCF | 16.7x |
Price Statistics
The stock is up 15.15% over 52 weeks and trades 2.56% above its 50-day average.
| Beta (1Y) | 0.79 |
|---|---|
| 52-Week Change | +15.15% |
| 1-Month Change | +5.12% |
| 3-Month Change | -5.54% |
| 6-Month Change | +33.80% |
| 5-Year Change | -69.72% |
| 10-Year Change | +10.73% |
| Total Return (1Y) | +15.15% |
| Total Return (3Y CAGR) | -22.76% |
| Total Return (5Y CAGR) | -18.80% |
| Return vs SPY (1Y) | +4.14% |
| Max Drawdown (1Y) | -30.29% |
| Max Drawdown (3Y) | -71.42% |
| Sharpe Ratio (1Y) | 0.32 |
| Correlation with SPY (1Y) | 0.23 |
| 50-Day Average | $47.20 |
| 200-Day Average | $42.01 |
| 52-Week Range | $31.44 to $54.80 |
| RSI (14 Days) | 48.7 |
| Average Volume (20 Days) | 387.83K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.49x current liabilities, and total debt is 0.77x shareholder equity.
| Current Ratio | 1.49x |
|---|---|
| Quick Ratio | 0.70x |
| Debt / Equity | 0.77x |
| Debt / EBITDA | 3.73x |
| Debt / FCF | 6.15x |
| Interest Coverage | 4.14x |
Returns and Efficiency
Return on invested capital is 5.16% over the last 12 months, against a 5-year average of 4.33%.
| Return on Equity (ROE) | 6.93% |
|---|---|
| Return on Assets (ROA) | 3.19% |
| Return on Invested Capital (ROIC) | 5.16% |
| Return on Capital Employed (ROCE) | 7.50% |
| ROE (5Y Average) | 4.64% |
| ROA (5Y Average) | 2.12% |
| ROIC (5Y Average) | 4.33% |
| Asset Turnover | 0.59x |
| Inventory Turnover | 1.61x |
| Receivables Turnover | 5.78x |
| Cash Conversion Cycle | 228 days |
Taxes
Income tax took 30.04% of pretax income over the last 12 months.
| Income Tax (TTM) | $31.53M |
|---|---|
| Effective Tax Rate | 30.04% |
Scores
CNMD has an Altman Z-Score of 2.00, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.00 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $1.37B over the last 12 months is up 1.62% from the 12 months before.
| Revenue | $1.37B |
|---|---|
| Revenue Growth (YoY) | +1.62% |
| Gross Profit | $788.34M |
| Operating Income | $135.59M |
| Pretax Income | $104.96M |
| Net Income | $73.43M |
| EBITDA | $218.81M |
| EBIT | $138.41M |
| Reported EPS (TTM) | $4.74 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 46.09% of the $2.30B in total assets.
| Cash and Equivalents | $47.97M |
|---|---|
| Total Debt | $815.87M |
| Net Debt | $767.89M |
| Net Debt Per Share | $25.66 |
| Working Capital | $223.08M |
| Shareholder Equity | $1.06B |
| Book Value Per Share | $35.42 |
| Tangible Book Value | -$293.64M |
| Total Assets | $2.30B |
| Total Liabilities | $1.24B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $13.62M of capital spending, operating cash flow left $132.69M of free cash flow.
| Operating Cash Flow | $146.31M |
|---|---|
| Capital Expenditures | $13.62M |
| Free Cash Flow | $132.69M |
| FCF Per Share | $4.43 |
| Depreciation and Amortization | $80.39M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 9.90%, against a 5-year average of 10.01%.
| Gross Margin | 57.57% |
|---|---|
| Operating Margin | 9.90% |
| Pretax Margin | 7.67% |
| Net Margin | 5.36% |
| EBITDA Margin | 15.98% |
| EBIT Margin | 10.11% |
| FCF Margin | 9.69% |
| Gross Margin (5Y Average) | 55.17% |
| Operating Margin (5Y Average) | 10.01% |
| Net Margin (5Y Average) | 3.44% |
Growth
Revenue grew 9.56% a year over 3 years, and EPS 20.27% a year.
| Revenue Growth (3Y CAGR) | +9.56% |
|---|---|
| Revenue Growth (5Y CAGR) | +9.77% |
| EPS Growth (3Y CAGR) | +20.27% |
| EPS Growth (5Y CAGR) | +16.37% |
| FCF Growth (3Y CAGR) | +135.31% |
| FCF Growth (5Y CAGR) | +23.98% |
| Operating Income Growth (3Y CAGR) | +13.57% |
| Book Value Per Share Growth (2Y CAGR) | +12.13% |
Dividends and Yields
CNMD does not pay a dividend. Its free cash flow yield is 9.16%.
| Earnings Yield | 9.80% |
|---|---|
| FCF Yield | 9.16% |
| Buyback Yield | 3.41% |
Stock Splits
The last split was a 3-for-2 forward split on Sep 10, 2001.
| Last Split Date | Sep 10, 2001 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 3:2 |
Peer Position
Against 7 similar companies, CNMD has the 5th highest P/E.
P/E RatioPeer median 29.3x
P/S RatioPeer median 2.9x
ROICPeer median -4.71%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +11.95%
| P/E Ratio | 10.2x vs 29.3x median |
|---|---|
| P/S Ratio | 1.1x vs 2.9x median |
| ROIC | 5.16% vs -4.71% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +1.62% vs +11.95% median |
Analyst Forecast
Consensus estimates put revenue growth at 1.85% and EPS growth at 1.50% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +1.85% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +1.50% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CNMD
What is CNMD's market cap?
CONMED has a market cap of $1.47B. Its enterprise value, which adds debt and subtracts cash, is $2.24B.
What is CNMD's P/E ratio?
CONMED has a trailing P/E ratio of 10.2x and a forward P/E of 10.4x.
How many shares of CNMD are outstanding?
CONMED has 29.93M shares outstanding. The count is down 3.32% from a year earlier.
Does CNMD pay a dividend?
No. CONMED does not pay a dividend.
How much debt does CNMD have?
CONMED has $815.87M of total debt and $47.97M of cash and equivalents, a net debt position of $767.89M.
CNMD pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts